If enacted, HB 6130 will change how Medicare covers certain diagnostic tests related to Alzheimer's disease. It specifically establishes coverage for tests that can detect the early stages of Alzheimer’s, which may positively influence patient outcomes by facilitating earlier treatments and support services. The bill lays out specific criteria for what constitutes an 'Alzheimer’s disease and related dementias early detection screening test', which emphasizes the importance of regulated and validated testing methods.
Summary
House Bill 6130, known as the Alzheimer's Screening and Prevention Act of 2025 (ASAP Act), aims to amend Title XVIII of the Social Security Act to provide Medicare coverage for blood-based dementia screening tests. This legislative initiative is part of a broader effort to enhance early detection and preventive care for Alzheimer's disease and related dementias, allowing individuals to access necessary screenings that can lead to timely interventions.
Contention
Points of contention surrounding the bill primarily revolve around the effectiveness and accessibility of such screening tests. Advocates argue that early detection can significantly alter the course of treatment and improve quality of life, which would offset costs in the long run. Conversely, some critics may raise concerns about the potential for misdiagnosis, the adequacy of Medicare funding, and whether the coverage will lead to equitable access among different populations, especially vulnerable groups who may benefit the most from early screening.
Requesting The Auditor To Assess The Social And Financial Effects Of Mandating Health Insurance Coverage For Brief Cognitive Assessments For Individuals Fifty Years Of Age And Older.
A bill to amend title XVIII of the Social Security Act to provide for certain cognitive impairment detection in the Medicare annual wellness visit and initial preventative physical examination.